Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease

Stem Cells

Volumn 26, Issue 7, 2008, Pages 1713-1722

  Meyerrose, Todd E ^a   Roberts, Marie ^a   Ohlemiller, Kevin K ^a   Vogler, Carole A ^b   Wirthlin, Louisa ^c   Nolta, Jan A ^a,c   Sands, Mark S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adult stem cells; Ex vivo gene therapy; Lentiviral vector; Lysosomal storage disease; Mesenchymal stem cells; Xenotransplantation

Indexed keywords

BETA GLUCURONIDASE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; LYSOSOME ENZYME;

ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; GENE THERAPY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MORQUIO SYNDROME; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; XENOTRANSPLANTATION;

ANIMALS; ELECTRORETINOGRAPHY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; GLUCURONIDASE; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; LYSOSOMAL STORAGE DISEASES; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MUCOPOLYSACCHARIDOSIS VII; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MURINAE; MUS;

EID: 55049118090     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0008     Document Type: Article

References (59)

1. Friedenstein AJ, Chailakhyan RK, Latsinik NV et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974;17:331-340.
2. Friedenstein AJ, Deriglasova UF, Kulagina NN et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2:83-92.
3. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74.
4. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
5. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-4295.
6. Campagnoli C, Roberts IA, Kumar S et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98:2396-2402.
7. Fukuchi Y, Nakajima H, Sugiyama D et al. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. STEM CELLS 2004;22:649-658.
8. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48.
9. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31:890-896.
10. Maitra B, Szekely E, Gjini K et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004;33:597-604.
11. Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model. J Orthop Res 2007;25:913-925.
12. Wakitani S, Goto T, Pineda SJ et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg Am 1994;76:579-592.
13. Tare RS, Howard D, Pound JC et al. Tissue engineering strategies for cartilage generation-micromass and three dimensional cultures using human chondrocytes and a continuous cell line. Biochem Biophys Res Commun 2005;333:609-621.
14. Stewart MC, Saunders KM, Burton-Wurster N et al. Phenotypic stability of articular chondrocytes in vitro: The effects of culture models, bone morphogenetic protein 2, and serum supplementation. J Bone Miner Res 2000;15:166-174.
15. Im GI, Kim DY, Shin JH et al. Repair of cartilage defect in the rabbit with cultured mesenchymal stem cells from bone marrow. J Bone Joint Surg Br 2001;83:289-294.
16. Crevensten G, Walsh AJ, Ananthakrishnan D et al. Intervertebral disc cell therapy for regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann Biomed Eng 2004;32:430-434.
17. Young RG, Butler DL, Weber W et al. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res 1998;16:406-413.
18. Awad HA, Butler DL, Boivin GP et al. Autologous mesenchymal stem cell-mediated repair of tendon. Tissue Eng 1999;5:267-277.
19. Petite H, Viateau V, Bensaid W et al. Tissue-engineered bone regeneration. Nat Biotechnol 2000;18:959-963.
20. Bruder SP, Kraus KH, Goldberg VM et al. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J Bone Joint Surg Am 1998;80:985-996.
21. Neubauer M, Hacker M, Bauer-Kreisel P et al. Adipose tissue engineering based on mesenchymal stem cells and basic fibroblast growth factor in vitro. Tissue Eng 2005;11:1840-1851.
22. Stosich MS, Mao JJ. Adipose tissue engineering from human adult stem cells: Clinical implications in plastic and reconstructive surgery. Plast Reconstr Surg 2007;119:71-83, discussion 84-85.
23. Nolta JA, Hanley MB, Kohn DB. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: Analysis of gene transduction of long-lived progenitors. Blood 1994;83:3041-3051.
24. Dao MA, Pepper KA, Nolta JA. Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model. STEM CELLS 1997;15:443-454.
25. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397.
26. Xin H, Kanehira M, Mizuguchi H et al. Targeted-delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. STEM CELLS 2007;25:1618-1626.
27. Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-1164.
28. Allay JA, Dennis JE, Haynesworth SE et al. LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. Hum Gene Ther 1997;8:1417-1427.
29. Suzuki K, Oyama M, Faulcon L et al. In vivo expression of human growth hormone by genetically modified murine bone marrow stromal cells and its effect on the cells in vitro. Cell Transplant 2000;9:319-327.
30. Bartholomew A, Patil S, Mackay A et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001;12:1527-1541.
31. Turgeman G, Pittman DD, Muller R et al. Engineered human mesenchymal stem cells: A novel platform for skeletal cell mediated gene therapy. J Gene Med 2001;3:240-251.
32. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
33. Koc ON, Day J, Nieder M et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-222.
34. Meyerrose TE, De Ugarte DA, Hofling AA et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. STEM CELLS 2007;25:220-227.
35. Neufeld EMJ. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill, 2001.
36. Sly WS, Quinton BA, McAlister WH et al. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 1973;82:249-257.
37. Birkenmeier EH, Davisson MT, Beamer WG et al. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989;83:1258-1266.
38. Birkenmeier EH, Barker JE, Vogler CA et al. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 1991;78:3081-3092.
39. Vogler C, Birkenmeier EH, Sly WS et al. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. Am J Pathol 1990;136:207-217.
40. Monroy MA, Ross FP, Teitelbaum SL et al. Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease. Bone 2002;30:352-359.
41. Hofling AA, Vogler C, Creer MH et al. Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood 2003;101:2054-2063.
42. Hofling AA, Devine S, Vogler C et al. Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol Ther 2004;9:856-865.
43. Hofling AA, Sands MS, Lublin DM et al. Collection of a mobilized peripheral blood apheresis product from a patient with mucopolysaccharidosis type VII and subsequent CD34+ cell isolation. J Clin Apher 2004;19:151-153.
44. Robbins PB, Yu XJ, Skelton DM et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 1997;71:9466-9474.
45. Robbins PB, Skelton DC, Yu XJ et al. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci U S A 1998;95:10182-10187.
46. Stripecke R, Carmen Villacres M, Skelton D et al. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999;6:1305-1312.
47. Dull T, Zufferey R, Kelly M et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998;72:8463-8471.
48. Glaser JH, Sly WS. Beta-glucuronidase deficiency mucopolysaccharidosis: methods for enzymatic diagnosis. J Lab Clin Med 1973;82:969-977.
49. Sands MS, Barker JE, Vogler C et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest 1993;68:676-686.
50. Ohlemiller KK, Vogler CA, Roberts M et al. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp Eye Res 2000;71:469-481.
51. Bensidhoum M, Chapel A, Francois S et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 2004;103:3313-3319.
52. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
53. Nitsche A, Becker M, Junghahn I et al. Quantification of human cells in NOD/SCID mice by duplex real-time polymerase-chain reaction. Haematologica 2001;86:693-699.
54. Eliopoulos N, Al-Khaldi A, Crosato M et al. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 2003;10:478-489.
55. Wolfe JH, Sands MS, Barker JE et al. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 1992;360:749-753.
56. Daly TM, Okuyama T, Vogler C et al. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum Gene Ther 1999;10:85-94.
57. Freeman BJ, Roberts MS, Vogler CA et al. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood 1999;94:2142-2150.
58. Sferra TJ, Backstrom K, Wang C et al. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol Ther 2004;10:478-491.
59. Donsante A, Levy B, Vogler C et al. Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J Inherit Metab Dis 2007;30:227-238.